Nevirapine Tablet
NDC Package 31722-505-01
Package Information
Nevirapine tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adults and pediatric patients 15 days and older [see Clinical Studies (14.1, 14.2)]. This formulation utilizes a tablet delivery system. Marketed by Camber Pharmaceuticals, Inc., this product is identified by NDC 31722-505 and is authorized under FDA application ANDA078584.
Identification & Billing
Clinical Specifications
- Cytochrome P450 2B6 Inducers - [MoA] (Mechanism of Action)
- Cytochrome P450 3A Inducers - [MoA] (Mechanism of Action)
- Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor - [EPC] (Established Pharmacologic Class)
- Non-Nucleoside Analog - [EXT]
- Non-Nucleoside Reverse Transcriptase Inhibitors - [MoA] (Mechanism of Action)
Regulatory & Marketing
Hierarchy Structure
- 31722 - Camber Pharmaceuticals, Inc.
- 31722-505 - Nevirapine
- 31722-505-01 - 100 TABLET in 1 BOTTLE
- 31722-505 - Nevirapine
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (31722-505). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 31722-505-01 identifies a specific commercial package of 100 tablet in 1 bottle of Nevirapine, a human prescription drug labeled by Camber Pharmaceuticals, Inc.. This tablet is formulated for oral use and contains nevirapine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Camber Pharmaceuticals, Inc. on May 23, 2012. The current certification is valid through December 31, 2027.
How is this Camber Pharmaceuticals, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 31722050501. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.